by | Jun 26, 2024 | Publications
Int J Cancer. 2024 Jun 25. doi: 10.1002/ijc.35063. Online ahead of print. ABSTRACT At the end of 2022, a huge tide of SARS-CoV-2 infection mainly Omicron BA.4/5 developed in China. Multiple myeloma (MM) patients suffered cancer deterioration and mortality from...
by | Jun 26, 2024 | Publications
Cancer Med. 2024 Jun;13(12):e7372. doi: 10.1002/cam4.7372. ABSTRACT BACKGROUND: Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a potent treatment for relapsed or refractory multiple myeloma, demonstrating significant clinical efficacy. Despite these...
by | Jun 26, 2024 | Publications
J Cell Mol Med. 2024 Jun;28(12):e18504. doi: 10.1111/jcmm.18504. ABSTRACT Despite remarkable advancements in the treatment of multiple myeloma (MM), relapse remains a challenge. However, the mechanisms underlying this disease remain unclear. This study aimed to...
by | Jun 26, 2024 | Publications
Br J Clin Pharmacol. 2024 Jun 23. doi: 10.1111/bcp.16133. Online ahead of print. ABSTRACT AIMS: To evaluate relationships between plasma concentrations of belantamab mafodotin, total monoclonal antibody, and its payload and changes in electrocardiogram (ECG)...
by | Jun 26, 2024 | Publications
Ann Acad Med Singap. 2023 Nov 29;52(11):590-600. doi: 10.47102/annals-acadmedsg.2022414. ABSTRACT INTRODUCTION: This study aimed to evaluate the clinical utility of positron emission tomography/magnetic resonance imaging (PET/MRI), especially in comparison with...
by | Jun 26, 2024 | Publications
Ann Acad Med Singap. 2023 Nov 29;52(11):601-624. doi: 10.47102/annals-acadmedsg.2023101. ABSTRACT AL amyloidosis is the most common form of systemic amyloidosis. However, the non-specific nature of presenting symptoms requires the need for a heightened clinical...
